Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a digital weight program and glucose monitor help control diabetes?

NCT ID NCT05935514

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a virtual weight control program combined with a continuous glucose monitor could help adults with type 2 diabetes lower their blood sugar levels. 152 overweight or obese adults with type 2 diabetes participated. The program used the WW (Weight Watchers) digital platform to support weight loss and better glucose control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

152 people

The number who actually took part.

Started

Aug 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 69 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18.0 - \<70 years of age * Participant-reported diagnosis of type 2 diabetes * HbA1c 7.5%-11% (inclusive) * Overweight or obesity (BMI 25-50 kg/m2 or BMI 23-50 kg/m2 if Asian or Asian American) * On stable regimen of medications that can affect weight or diabetes outcomes for at least 3 months (brief regimens of medications such as antibiotics, steroids, etc. are permitted) * Weight stable (+/- 5%) over previous: * 3 months * Or 6 months if on medications that impact weight like GLP-1 diabetes medications. * Willingness to attend weekly WW Virtual Workshops and Weekly Check-Ins and participate in WW Digital program * Willingness to lose weight through a diet and lifestyle change intervention * Access to a smartphone/tablet that can download the WW app * Willingness to wear a continuous glucose monitor for duration of the trial * Willing and able to provide a valid email address for use in the study * Be able to communicate (oral and written) in English * Be under the care of a physician who will be responsible for managing the subject's diabetes and a participant who is willing to give release to provide their treating MD with information about the trial * Be able to provide informed consent Exclusion Criteria: * Participation in a structured, formal weight control program within the past 3 months * Use of a continuous glucose monitor within the past 3 months (consistently for 4 weeks or more where blood sugar recordings could be seen/monitored in real time) * Weight loss surgery (sleeve or bypass) * History of major surgery within 6 months of enrollment * Type 1 diabetes * More than 1 severe hypoglycemic event (requiring emergency medical services) in the past 12 months, unless the participant's physician provides written clearance for participation * Any history of significant kidney or liver disease or malnutrition that in investigator judgment should exclude participation * Hemoglobinopathy that interferes with measurement of HbA1c * Class II or higher congestive heart failure * Unstable heart disease (an ongoing workup or treatment for a cardiac symptom such as unstable angina, coronary ischemia) * Presence of implanted cardiac defibrillator * Blood pressure ≥160/100 mm Hg. If a potential participant has a blood pressure ≥160/100 mm Hg it is acceptable to re-test this potential participant within one week of the original test * Thyroid disease for which the participant is untreated or has had treatment changed within the last 6 months. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 2 months is acceptable * Orthopedic limitations that would interfere with ability to engage in regular physical activity * Uncontrolled gastrointestinal disorders including chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, chronic diarrhea or active gallbladder disease * Current cancer or cancer treatment, or a history of cancer or cancer treatment within the last 3 years. Exceptions include 1) successfully resected non-melanoma carcinoma of the skin, 2) basal or squamous cell skin cancer, 3) stage 0 non-invasive carcinoma of the cervix, 4) stage 0 non-invasive prostate cancer * Dementia, psychiatric illness, or substance abuse that may interfere with adherence (e.g., illness that is currently unstable or resistant to first-line therapy; substance abuse in the past year) * History of clinically diagnosed eating disorder including anorexia nervosa or bulimia nervosa. * Women who are pregnant, lactating, trying to become pregnant or unwilling to use an effective means of birth control * Currently consuming \>14 alcoholic drinks (1 drink = 12 fl oz beer, 4 fl oz wine or 1.5 fl oz liquor) per week and unwilling to limit intake to less than 3 drinks per day during study participation * Participation in another clinical trial within 30 days prior to enrollment * Participation in WW anytime in the last 12 months * Any other condition or factor which in the opinion of the study physician or investigator makes it inadvisable for the candidate to participate in the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana, 70808, United States

  • Stanford University

    Stanford, California, 94305, United States

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.